← Leaderboards
Marka Crittenden
Providence Portland Medical Center
$2,669,247
Attributed
$2,843,878
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $707.4K · FY2013–20$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$2,843,878 · 4
By mechanism
R01$1,875,866 · 1
R21$803,012 · 2
R03$165,000 · 1
Top collaborators
- Brendan D Curti2 shared
Most similar at Providence Portland Medical Center
Same institution · by research overlap
- William L Redmond$2,939,722
- Brendan D Curti$3,242,071
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorResponseT-LymphocyteImmune ResponseImmunotherapyAntigensPathway InteractionsResearch DesignT Cell ResponseRadiationRadiation TherapyImmuneCellsAdaptive ImmunityAdjuvantPalliationPreventMalignant Neoplasm Of PancreasMouse ModelCancer CellImmunityCancer PatientAntigen PresentationDistant
Grant awards (11)
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.$377,438
R01 · FY2020 · CA · contact PI
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.$366,114
R01 · FY2019 · CA · contact PI
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.$377,438
R01 · FY2018 · CA · contact PI
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.$377,438
R01 · FY2017 · CA · contact PI
Increasing the potency of Listeria monocytogenes-based vaccines by eliminating vaccine-related gamma delta T cell responses.$206,250
R21 · FY2017 · AI · contact PI
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.$377,438
R01 · FY2016 · CA · contact PI
Increasing the potency of Listeria monocytogenes-based vaccines by eliminating vaccine-related gamma delta T cell responses.$247,500
R21 · FY2016 · AI · contact PI
Generation of a novel fusion protein to redirect macrophage differentiation following radiation therapy.$82,500
R03 · FY2016 · CA · contact PI
Generation of a novel fusion protein to redirect macrophage differentiation following radiation therapy.$82,500
R03 · FY2015 · CA · contact PI
Clinical and Immunological Effects of SBRT and IL-2 in Metastatic Melanoma$156,122
R21 · FY2014 · CA · contact PI
Clinical and Immunological Effects of SBRT and IL-2 in Metastatic Melanoma$193,140
R21 · FY2013 · CA · contact PI